REVIEW PAPER
Metabolic syndrome and professional aptitude
Submission date: 2015-09-30
Final revision date: 2015-12-11
Acceptance date: 2015-12-11
Publication date: 2016-01-11
Medical Studies 2015;31(4):286-294
KEYWORDS
TOPICS
ABSTRACT
The development of civilisation has resulted in a growing problem of metabolic diseases, including metabolic syndrome. Scientific studies show that this disease is an epidemic of the 21st century. Metabolic syndrome is a collection of mutually related metabolic factors, such as obesity, impaired glucose tolerance, lipid disorders, arterial hypertension, and pro-inflammatory and prothrombotic state, increasing the risk of the development of atherosclerosis and type 2 diabetes, and their cardiovascular complications. Considering the scale of the prevalence of metabolic syndrome, the causes of its development and diagnostic criteria are the main contemporary directions of scientific research. The study presents an analysis of the relevant literature with respect to terminology, diagnostic criteria, and pathogenesis of metabolic syndrome. The second section of the study discusses the degree of epidemiological risk due to metabolic syndrome and its individual components among the adult Polish population. The effect of this phenomenon on professional competence is also taken into consideration.
REFERENCES (48)
2.
Erkelens DW, de Bruin TW, Castro Cabezas M. Tulp syndrome. Lancet 1993; 342: 1536-7.
3.
Enzi G, Busetto L, Inelmen EM, et al. Historical perspective: visceral obesity and related comorbidity in Joannes Baptista Morgagni’s ‘De sedibus et causis morborum per anatomen indagata’. Int J Obes Relat Metab Disord 2003; 27: 534-5.
4.
Kylin E. Studien über das Hypertonie-Hyperglykämie-Hyperurikämiesyndrom. Zentralblatt für Innere Medizin 1923; 44: 105-27.
5.
Avogaro P, Crepaldi G, Enzi G, Tiengo A. Association of hyperlipidemia an mild obesity. Acta Diabetol Lat 1967; 4: 36-41.
7.
Węgierko J. Znaczenie praktyczne podziału cukrzycy na poszczególne jej postacie. Pol Arch Med Wewn 1955; 25: 791-7.
9.
Hanefeld M, Leonhardt W. Das metabolische Syndrome. Dt. Gesundh-Wesen1981; 36: 545-51.
10.
Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
11.
Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989; 149: 1514-20.
12.
Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350-7.
13.
Wyrzykowski B. Historia zespołu metabolicznego. Choroby Serca i Naczyń 2005; 4: 206-13.
14.
Lemieux I, Pascot A, Couillard C, et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 2000; 102: 179-84.
15.
Alberti KG, Zimmet PZ. Defi nition, diagnosis and classifi cation of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus: provisional report of WHO consultation. Diabetes Med 1998; 15: 539-53.
16.
Grundy SM, Hansen B, Smith SC, et al. Clinical management of metabolic syndrome. Report of the American Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004; 109: 551-6.
17.
Balkau B, Charles MA. Comment of the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999; 16: 442-3.
18.
Balkau B, Charles MA, Drivsholm T, et al. The European Group for the Study of Insulin Resistance (EGIR): Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002; 28: 364-76.
19.
Lewis GF, Carpentier A, Adeli K, et al. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002; 23: 201-29.
20.
Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-52.
21.
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
22.
National Cholesterol Education Program National Heart, Lung, and Blood Institutes of Health NIH Publication No. 02-5215 September 2002: Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
23.
Liao Y, Kwon S, Shaughnessy S, et al. Critical evaluation of Adult Treatment Panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care 2004; 27: 978-83.
24.
Einhorn D, Reaven GM, Cobin RH, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003; 9: 237-52.
25.
Alberti G, Zimmet PZ, Shaw J, et al. International Diabetes Federation 2006: the IDF consensus worldwide definition of the metabolic syndrome. http://www.idf.org/webdata/doc... nal.pdf (23.06.2015).
26.
Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome. A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-5.
27.
Carr DB, Utzschneider KM, Hull RL, et al. Intraabdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004; 53: 2087-94.
29.
Snyder EE, Walts B, Perusse L, et al. The human obesity gene map: the 2003 update. Obes Res 2004; 12: 369-439.
30.
Stein CM, Song Y, Elston RC, et al. Structural equation model-based genome scan for the metabolic syndrome. BMC Genet 2003; 4 (Supp1. 1): S99.
31.
Tang W, Miller MB, Rich SS, et al. Linkage analysis of a composite factor for the multiple metabolic syndrome: the National Heart, Lung, and Blood Institute Family Heart Study. Diabetes 2003; 52: 2840-7.
32.
Semenkovich CF. Insulin resistance and atherosclerosis. J Clin Invest 2006; 116: 1813-22.
33.
Pacholczyk M, Ferenc T, Kowalski J. Zespół metaboliczny. Część II: patogeneza zespołu metabolicznego i jego powikłań. Postępy Hig Med Dosw 2008; 62: 543-58.
34.
Ford ES. Risk for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome. A summary of the evidence. Diabetes Care 2005; 28: 1769-78.
35.
Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-9.
36.
Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-16.
37.
Wyrzykowski B, Zdrojewski T, Sygnowska E, et al. Epidemiologia zespołu metabolicznego w Polsce. Wyniki programu WOBASZ. Kardiol Pol 2005; 63 (Suppl. 4): 1-4.
38.
Zdrojewski T, Bandosz P, Szpakowski P, et al. Rozpowszechnienie głównych czynników ryzyka chorób układu sercowo-naczyniowego w Polsce. Wyniki badania NATPOL PLUS. Kardiol Pol 2004; 61 (Suppl. IV): IV1-26.
39.
Broda G, Szcześniewska D, Rywik S. Częstość występowania zespołu metabolicznego w populacji osób dorosłych Warszawy. Med Metab 2003; 7: 225-9.
40.
Tatoń J, Czech A, Bernas M. Otyłość: zespół metaboliczny. Wyd. Lekarskie PZWL, Warsaw 2007; 26-350.
41.
Cymerys M, Pupek-Musialik D. Nowe czynniki ryzyka wieńcowego u otyłych chorych z zespołem metabolicznym. In: Otyłość i zespół metaboliczny od teorii do praktyki. Pupek-Musialik D (ed.). Via Medica, Gdansk 2007; 66-77.
42.
King H, Aubert R, Herman W. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414-31.
43.
Jarret RJ, Shipley MJ. Type 2 (non-insulin-dependent) diabetes mellitus and cardiovascular disease – putative association via common antecedens: further evidence from the Whitehall Study. Diabetologia 1988; 31: 737-41.
44.
Janeczko D, Kopczyński J, Lewandowski Z, et al. Umieralność z powodu chorób układu krążenia u chorych na cukrzycę typu 2. Przegląd Lek 2000; 57 (Suppl. 4): 3.
45.
LIPIDOGRAM 5 LAT – Ogólnopolskie badanie epidemiologiczne zaburzeń lipidowych oraz wybranych czynników ryzyka chorób sercowo-naczyniowych w warunkach Podstawowej Opieki Zdrowotnej. KLRWP, Poznań 2013; available at: http://www.termedia.pl (29.06.2015).
46.
Thompson PD, Buchner D, Pina IL, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease. A statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation and Prevention) and the Council on Nutrition, Physical Activity and Metabolism (Subcommittee on Physical Activity). Circulation 2003; 107: 3109-16.
47.
Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
Share
RELATED ARTICLE
| eISSN: | 2300-6722 |
| ISSN: | 1899-1874 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
